Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.75 -0.34 (-3.07%)
Streaming Delayed Price Updated: 1:44 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion ↗
Intellia will receive up to $920 million in payments for five potential treatments. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022 ↗
Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61,... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
News headline image
Analyst Ratings For Intellia Therapeutics ↗
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter: 
Via Benzinga
News headline image
Intellia Therapeutics & UiPath Elliott Wave Analysis ↗
US Stocks NTLA &PATH technical analysis, Elliott Wave forecast & trading. 
Via Talk Markets
News headline image
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today ↗
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 32.37% on an annualized basis. Buying $1,000 In NTLA: 5 years ago, an investor could have... 
Via Benzinga
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
News headline image
What 4 Analyst Ratings Have To Say About Intellia Therapeutics ↗
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers SomaLogic (NASDAQ:SLGC) shares mo... 
Via Benzinga
News headline image
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
News headline image
36 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and... 
Via Benzinga
News headline image
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
Via The Motley Fool
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
Looking for Growth in Small and Mid Cap Life Science Stocks ↗
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
News headline image
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript ↗
NTLA earnings call for the period ending October 3, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock ↗
David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What... 
Via Benzinga
Topics Regulatory Compliance
News headline image
2 Gene-Editing Stocks to Have on Your Radar Right Now ↗
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
Via The Motley Fool
News headline image
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
News headline image
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients ↗
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.